Uni-Bio Science Group Ltd. (HK:0690)
:0690
Top Page
Uni-Bio Science Group Ltd.
(0690)
Select Model
Select Model
Rating:66Neutral
Price Target:
HK$0.14
▲(4.62% Upside)
Action:ReiteratedDate:11/28/25
The stock score is primarily influenced by strong financial performance and attractive valuation. However, technical indicators suggest bearish momentum, which tempers the overall score. The absence of operating cash flows is a concern that needs monitoring.
Positive Factors
Revenue & margin strength
Sustained double-digit revenue growth alongside very high gross margins and improving EBIT/EBITDA margins indicate durable product economics and pricing power. This supports long-term reinvestment in R&D and commercial expansion and underpins persistent profitability over multiple years.
Negative Factors
No operating cash flow in 2024
Reported absence of operating cash flow despite accounting profits suggests weak cash conversion, potential working capital strain, or timing issues. Over months this can pressure liquidity, constrain R&D/capex funding, and force external financing that dilutes financial resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & margin strength
Sustained double-digit revenue growth alongside very high gross margins and improving EBIT/EBITDA margins indicate durable product economics and pricing power. This supports long-term reinvestment in R&D and commercial expansion and underpins persistent profitability over multiple years.
Read all positive factors
Uni-Bio Science Group Ltd. (0690) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$595.71M
Dividend Yield2.37%
Average Volume (3M)5.61M
Price to Earnings (P/E)2.2
Beta (1Y)-0.06
Revenue Growth15.97%
EPS Growth-3.77%
CountryHK
Employees487
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)<0.01
Shares Outstanding5,971,228,000
10 Day Avg. Volume4,310,360
30 Day Avg. Volume5,609,336
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.13
Price to Sales (P/S)0.67
P/FCF Ratio12.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Uni-Bio Science Group Ltd. Business Overview & Revenue Model
Company Description
Uni-Bio Science Group Ltd. (0690) is a biotechnology company based in Hong Kong, primarily engaged in the research, development, manufacturing, and commercialization of high-quality biopharmaceutical products. The company focuses on the fields of ...
How the Company Makes Money
Uni-Bio Science Group Ltd. generates revenue through multiple streams, focusing primarily on the sales of its biopharmaceutical products. The company earns income by marketing its proprietary drugs and therapies, particularly in oncology and autoi...
Uni-Bio Science Group Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 589.59M | 552.98M | 484.72M | 440.32M | 353.40M | 208.78M |
| Gross Profit | 484.56M | 461.07M | 392.82M | 334.88M | 277.01M | 181.09M |
| EBITDA | 122.21M | 113.56M | 93.56M | 61.21M | 1.31M | -49.95M |
| Net Income | 91.35M | 82.77M | 70.88M | 38.51M | -19.59M | -71.32M |
Balance Sheet | ||||||
| Total Assets | 556.05M | 517.55M | 409.99M | 292.47M | 267.59M | 252.72M |
| Cash, Cash Equivalents and Short-Term Investments | 170.51M | 183.90M | 129.24M | 98.22M | 83.61M | 61.04M |
| Total Debt | 108.00M | 115.19M | 56.30M | 22.67M | 5.60M | 3.14M |
| Total Liabilities | 173.20M | 191.91M | 152.82M | 97.72M | 93.29M | 63.31M |
| Stockholders Equity | 382.85M | 325.64M | 257.17M | 194.75M | 174.31M | 189.41M |
Cash Flow | ||||||
| Free Cash Flow | 32.93M | 28.71M | 39.11M | 20.23M | 3.61M | -28.45M |
| Operating Cash Flow | 70.93M | 66.71M | 98.85M | 48.66M | 12.04M | -15.47M |
| Investing Cash Flow | -45.62M | -168.07M | -76.14M | -27.03M | 42.12M | -24.65M |
| Financing Cash Flow | -26.60M | 27.79M | 24.51M | 2.58M | 478.00K | -5.41M |
Uni-Bio Science Group Ltd. Technical Analysis
Negative
0.13
Price Trends
0.11
Negative
0.11
Negative
0.13
Negative
Market Momentum
>-0.01
Positive
38.09
Neutral
20.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0690, the sentiment is Negative. The current price of 0.13 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.11, and above the 200-day MA of 0.13, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.09 is Neutral, neither overbought nor oversold. The STOCH value of 20.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0690.
Uni-Bio Science Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$595.71M | 2.22 | 25.79% | 2.37% | 15.97% | -3.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$1.30B | -1.67 | -70.71% | ― | ― | 81.67% | |
44 Neutral | HK$717.58M | -2.18 | 191.92% | ― | ― | 83.89% | |
43 Neutral | HK$1.25B | -2.47 | -27.44% | ― | -57.84% | 24.58% | |
41 Neutral | HK$1.06B | -2.53 | -22.45% | ― | -8.43% | 64.33% | |
41 Neutral | HK$912.08M | -1.73 | -75.15% | ― | 2.45% | 2.58% |
* Healthcare Sector Average
HK:0690
Uni-Bio Science Group Ltd.
0.10
0.04
78.57%
HK:9939
Kintor Pharmaceutical Ltd
2.64
1.53
137.75%
HK:1244
3D Medicines, Inc.
4.10
0.58
16.48%
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
2.19
0.80
57.55%
HK:2257
Sirnaomics Ltd.
6.54
3.49
114.43%
HK:6628
Transcenta Holding Limited
2.82
1.68
147.37%
Uni-Bio Science Group Ltd. Corporate Events
Uni-Bio Science Strikes Tripartite R&D Pact to Advance Regenerative Medicine Pipeline
Dec 30, 2025
Uni-Bio Science Group Limited has signed a tripartite strategic cooperation agreement with the National Engineering Research Center for Cell Growth Factor Drugs and Protein Formulations of Wenzhou Medical University and the Wenzhou Ouhai District ...
Uni-Bio Science Extends Connected Loans to 2027 Under Hong Kong Listing Rules
Dec 29, 2025
Uni-Bio Science Group Limited has extended the maturity of existing loans advanced by a wholly owned subsidiary to connected parties Dongguan Taili and Guangzhou Taili from 31 December 2025 to 31 December 2027, under new extension agreements signe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.